Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 09 2024
0mins
Source: NASDAQ.COM
Overview of iShares U.S. Medical Devices ETF (IHI): Launched in 2006 and sponsored by Blackrock, IHI is a passively managed ETF focused on the Healthcare - Medical Devices sector, with over $4.86 billion in assets and an annual expense ratio of 0.40%. It aims to match the performance of the Dow Jones U.S. Select Medical Equipment Index.
Performance and Investment Insights: The ETF has shown a return of approximately 21.78% over the past year, with a medium risk profile and a Zacks ETF Rank of 2 (Buy). Investors are encouraged to review individual holdings, which are heavily concentrated in the healthcare sector, with Abbott Laboratories being the largest holding at 16.93%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 365.850
Low
390.00
Averages
430.32
High
465.00
Current: 365.850
Low
390.00
Averages
430.32
High
465.00
About SYK
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stryker Launches T2 Alpha Humerus Nailing System for Enhanced Fracture Treatment
- Product Innovation: Stryker's T2 Alpha Humerus Nailing System utilizes SOMA technology to enhance fixation stability for complex humeral fractures by providing personalized anatomical fit, thereby improving surgical success rates and patient recovery outcomes.
- Surgical Efficiency Boost: The system simplifies surgical procedures through intuitive instrumentation and guided targeting, enabling surgeons to operate more efficiently in the operating room while reducing tray requirements, thus enhancing hospital operational efficiency.
- Technical Advantages: The T2 Alpha system features multiplanar screw fixation and active intraoperative compression capabilities, allowing for controlled fracture reduction of up to 6mm, significantly improving the precision and stability of fracture treatment compared to traditional methods.
- Market Outlook: With the launch of this system, Stryker further solidifies its leadership position in the medical technology sector, expected to drive growth in the trauma market and meet surgeons' demands for efficient and reliable treatment solutions.
See More
Stryker Launches Mako RPS Handheld Robotic System for Total Knee
- Product Market Release: Stryker announced the limited market release of Mako RPS (Robotic Power System) aimed at expanding its robotics platform, leveraging the company's successful legacy in robotics and power tools, which is expected to attract surgeons interested in robotic technology.
- Integrated Technical Advantages: Mako RPS is compatible with Stryker's Triathlon® Total Knee System, offering intraoperative planning and robotically enabled cutting features, utilizing patented technology that responds to surgeons' hand movements to ensure alignment with surgical plans.
- Industry Leadership Position: The Mako brand has established itself as a standard of care in orthopaedics, having completed over 2 million procedures across 46 countries in nearly 20 years, further solidifying Stryker's leadership in the medical technology sector.
- Diverse Ecosystem: Mako RPS seamlessly integrates with Stryker's multi-specialty guidance platform, Q Guidance System, enhancing the flexibility within the company's orthopaedic technologies ecosystem, aimed at improving patient and healthcare outcomes.
See More
Stryker Launches Mako RPS Handheld Robotics for Total Knee
- Product Market Release: Stryker announced the limited market release of Mako RPS (Robotic Power System), aiming to expand into a new robotics platform by combining its established robotics and power tool technologies, which is expected to enhance the company's market share in orthopedic surgery.
- Surgical Workflow Optimization: Mako RPS is compatible with Stryker's Triathlon® Total Knee System, providing a user-friendly solution for surgeons to experience the potential benefits of robotic technology within a familiar manual power tool environment, thereby improving surgical efficiency and patient outcomes.
- Technological Innovation: Mako RPS features intraoperative planning and robotically enabled saw capabilities, utilizing Stryker's patented active adjustment technology that responds to the surgeon's hand movements in real-time, ensuring alignment with the surgical plan and enhancing surgical precision.
- Industry Leadership: With nearly 20 years of experience in orthopedic robotics and over 2 million procedures performed across 46 countries, the Mako brand has established itself as a standard of care in orthopedics, and the launch of Mako RPS will further solidify Stryker's leadership position in the medical technology sector.
See More
Stryker Declares Quarterly Dividend of $0.88 per Share
- Quarterly Dividend Announcement: Stryker Corporation has declared a quarterly dividend of $0.88 per share, consistent with previous distributions, indicating stable cash flow and a commitment to shareholder returns, which is likely to bolster investor confidence.
- Dividend Yield: The forward yield stands at 0.98%, reflecting the company's attractiveness in the current market environment, potentially drawing in investors seeking stable income.
- Shareholder Record Date: The dividend will be payable on April 30, with a record date of March 31 and an ex-dividend date also on March 31, ensuring shareholders receive their payouts promptly, which may enhance loyalty towards the company.
- Future Growth Outlook: Stryker projects organic sales growth of 8% to 9.5% for 2026 while advancing margin expansion and new product launches, indicating a proactive strategic positioning in a competitive market landscape.
See More
Apple's Earnings Beat Expectations but Shares Decline
- Apple's Strong Performance: Apple reported a fiscal first-quarter earnings per share of $2.84, exceeding the $2.67 expected by analysts, with revenue hitting $143.76 billion, significantly above the $138.48 billion forecast, driven by robust sales of the iPhone 17 models, despite a 1.3% drop in share price.
- Metals Miners Decline: Shares of Newmont and Freeport-McMoRan fell 9.6% and 7.6%, respectively, primarily due to a decline in gold and silver prices, reflecting market concerns over metal demand, which could impact future investment decisions.
- Chevron's Earnings Beat: Chevron's fourth-quarter adjusted earnings reached $1.52 per share, surpassing the $1.45 consensus from analysts, bolstered by record oil production, leading to a share price increase of over 1%, indicating strong performance in the oil market.
- Deckers' Positive Outlook: Deckers Outdoor's 2026 outlook projects earnings per share between $6.80 and $6.85, with revenue expectations of $5.4 billion to $5.43 billion, both exceeding market expectations, resulting in a 16.1% surge in share price.
See More
Stryker Corp Stock Rises 3.3% Following Increased Annual Profit Outlook
Stock Performance: Stryker Corporation's shares increased by 3.3%.
Profit Forecast: The rise in share price follows the company raising its annual profit forecast.
See More
Stryker Launches T2 Alpha Humerus Nailing System for Enhanced Fracture Treatment
- Product Innovation: Stryker's T2 Alpha Humerus Nailing System utilizes SOMA technology to enhance fixation stability for complex humeral fractures by providing personalized anatomical fit, thereby improving surgical success rates and patient recovery outcomes.
- Surgical Efficiency Boost: The system simplifies surgical procedures through intuitive instrumentation and guided targeting, enabling surgeons to operate more efficiently in the operating room while reducing tray requirements, thus enhancing hospital operational efficiency.
- Technical Advantages: The T2 Alpha system features multiplanar screw fixation and active intraoperative compression capabilities, allowing for controlled fracture reduction of up to 6mm, significantly improving the precision and stability of fracture treatment compared to traditional methods.
- Market Outlook: With the launch of this system, Stryker further solidifies its leadership position in the medical technology sector, expected to drive growth in the trauma market and meet surgeons' demands for efficient and reliable treatment solutions.
See More
Stryker Launches Mako RPS Handheld Robotic System for Total Knee
- Product Market Release: Stryker announced the limited market release of Mako RPS (Robotic Power System) aimed at expanding its robotics platform, leveraging the company's successful legacy in robotics and power tools, which is expected to attract surgeons interested in robotic technology.
- Integrated Technical Advantages: Mako RPS is compatible with Stryker's Triathlon® Total Knee System, offering intraoperative planning and robotically enabled cutting features, utilizing patented technology that responds to surgeons' hand movements to ensure alignment with surgical plans.
- Industry Leadership Position: The Mako brand has established itself as a standard of care in orthopaedics, having completed over 2 million procedures across 46 countries in nearly 20 years, further solidifying Stryker's leadership in the medical technology sector.
- Diverse Ecosystem: Mako RPS seamlessly integrates with Stryker's multi-specialty guidance platform, Q Guidance System, enhancing the flexibility within the company's orthopaedic technologies ecosystem, aimed at improving patient and healthcare outcomes.
See More
Stryker Launches Mako RPS Handheld Robotics for Total Knee
- Product Market Release: Stryker announced the limited market release of Mako RPS (Robotic Power System), aiming to expand into a new robotics platform by combining its established robotics and power tool technologies, which is expected to enhance the company's market share in orthopedic surgery.
- Surgical Workflow Optimization: Mako RPS is compatible with Stryker's Triathlon® Total Knee System, providing a user-friendly solution for surgeons to experience the potential benefits of robotic technology within a familiar manual power tool environment, thereby improving surgical efficiency and patient outcomes.
- Technological Innovation: Mako RPS features intraoperative planning and robotically enabled saw capabilities, utilizing Stryker's patented active adjustment technology that responds to the surgeon's hand movements in real-time, ensuring alignment with the surgical plan and enhancing surgical precision.
- Industry Leadership: With nearly 20 years of experience in orthopedic robotics and over 2 million procedures performed across 46 countries, the Mako brand has established itself as a standard of care in orthopedics, and the launch of Mako RPS will further solidify Stryker's leadership position in the medical technology sector.
See More
Stryker Declares Quarterly Dividend of $0.88 per Share
- Quarterly Dividend Announcement: Stryker Corporation has declared a quarterly dividend of $0.88 per share, consistent with previous distributions, indicating stable cash flow and a commitment to shareholder returns, which is likely to bolster investor confidence.
- Dividend Yield: The forward yield stands at 0.98%, reflecting the company's attractiveness in the current market environment, potentially drawing in investors seeking stable income.
- Shareholder Record Date: The dividend will be payable on April 30, with a record date of March 31 and an ex-dividend date also on March 31, ensuring shareholders receive their payouts promptly, which may enhance loyalty towards the company.
- Future Growth Outlook: Stryker projects organic sales growth of 8% to 9.5% for 2026 while advancing margin expansion and new product launches, indicating a proactive strategic positioning in a competitive market landscape.
See More
Apple's Earnings Beat Expectations but Shares Decline
- Apple's Strong Performance: Apple reported a fiscal first-quarter earnings per share of $2.84, exceeding the $2.67 expected by analysts, with revenue hitting $143.76 billion, significantly above the $138.48 billion forecast, driven by robust sales of the iPhone 17 models, despite a 1.3% drop in share price.
- Metals Miners Decline: Shares of Newmont and Freeport-McMoRan fell 9.6% and 7.6%, respectively, primarily due to a decline in gold and silver prices, reflecting market concerns over metal demand, which could impact future investment decisions.
- Chevron's Earnings Beat: Chevron's fourth-quarter adjusted earnings reached $1.52 per share, surpassing the $1.45 consensus from analysts, bolstered by record oil production, leading to a share price increase of over 1%, indicating strong performance in the oil market.
- Deckers' Positive Outlook: Deckers Outdoor's 2026 outlook projects earnings per share between $6.80 and $6.85, with revenue expectations of $5.4 billion to $5.43 billion, both exceeding market expectations, resulting in a 16.1% surge in share price.
See More
Stryker Corp Stock Rises 3.3% Following Increased Annual Profit Outlook
Stock Performance: Stryker Corporation's shares increased by 3.3%.
Profit Forecast: The rise in share price follows the company raising its annual profit forecast.
See More
